There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Oncolytics Biotech (ONCY – Research Report) and IN8bio (INAB – Research Report) with bullish sentiments.
Oncolytics Biotech (ONCY)
In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Oncolytics Biotech, with a price target of C$9.00. The company’s shares closed last Monday at $1.66.
According to TipRanks.com, Roy has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Oncolytics Biotech with a $6.77 average price target, representing a 300.6% upside. In a report issued on May 26, H.C. Wainwright also reiterated a Buy rating on the stock with a $15.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
IN8bio (INAB)
Mizuho Securities analyst Mara Goldstein maintained a Buy rating on IN8bio today and set a price target of $12.00. The company’s shares closed last Monday at $2.81.
According to TipRanks.com, Goldstein is a 2-star analyst with an average return of
Currently, the analyst consensus on IN8bio is a Strong Buy with an average price target of $11.33, a 271.5% upside from current levels. In a report released today, EF Hutton also reiterated a Buy rating on the stock with a $8.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ONCY:
- Oncolytics Biotech Dives after Breast Cancer Treatment Disappoints
- Oncolytics Biotech® Reports First Quarter 2023 Financial Results and Operational Highlights
- ONCY Earnings this Week: How Will it Perform?
- Oncolytics management to meet virtually with Cantor Fitzgerald
- Oncolytics management to meet with Oppenheimer
